ClinicalTrials.gg
RecruitingNCT05989581CHAP2Updated Aug 11, 2026

Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project

A Phase 1 interventional study of Labetalol or Nifedipine in Hypertension in Pregnancy, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to female participants aged 14 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by University of Alabama at Birmingham · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
14 Years to 89 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Hypertension, Pregnancy-Induced with a site in United States — 30 open to participants now, 40 under way, 4 of them phase 3. Hypertension, Pregnancy-Induced · United States.

Planned enrollment
63rd of 89
74 · median 120
Started
2024
with 12 others
Phase 1
4 of 106
1 open now
Primary completion
2026-12
later than 10 of 39 live
Registered
71st of 106
by date
Lead sponsor
3 of 106
University of Alabama at Birmingham

Among the 106 studies in Hypertension, Pregnancy-Induced with a site in United States, this one is the 63rd largest by planned enrollment of the 89 interventional ones that give a count, is one of 13 that started in 2024, is one of 4 in phase 1, reaches primary completion later than 10 of the 39 other live ones, and was the 71st registered.

Hypertension, Pregnancy-Induced

262 studies on the registry are indexed under Hypertension, Pregnancy-Induced; 70 are open to participants now.

Browse Hypertension, Pregnancy-Induced studies →

Open to participants now

30 of the 106 studies in Hypertension, Pregnancy-Induced with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Hypertension, Pregnancy-Induced studies recruiting now, 23 (43%) set no upper age limit and 29 (55%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 14 Years to 89 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Hypertension, Pregnancy-Induced with a site in United States, or all of them as a file.
02

Study summary

The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes. The primary objective of this pilot study is to determine if anti-HTN treatment to BP\<130/80mmHg in pregnant patients with stage 1 HTN is associated with a difference in birthweight percentile at delivery. Patients with stage 1 hypertension in pregnancy will be randomized to BP goals of \<130/80mmHg or usual care to treatment only if BPs ≥140/90mmHg. For this pilot, the investigator will randomize a total of 74 eligible participants, 37 to active treatment to BP\<130/80mmHg and 37 to usual care.

03

Conditions studied

  • Hypertension in Pregnancy
04

Who can participate

Ages eligible
14 Years to 89 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Viable singleton gestation
  • No fetal anomalies
  • Blood pressures 130-139/80-89mmHg on two occasions at least 4 hours apart prior to 20 weeks gestation
  • Planning to deliver at UAB Hospital
  • No indication for pregnancy termination
  • Receiving care at the UAB prenatal clinics

Exclusion criteria

Exclusion Criteria:

  • Declines Randomization
  • Known diagnosis of chronic hypertension ( BP ≥ 140/90mmHg) or current antihypertensive medication use
  • Fetal demise diagnosed prior to enrollment
  • Known major structural of chromosomal abnormalities prior to enrollment
  • to antihypertensive (Nifedipine/ Labetalol)
  • Comorbidities requiring BP goals \< 130/80mmHg
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    BP goal <130/80mmHg

    Drug: Labetalol or Nifedipine

  • No intervention
    BP goal <140/90 (usual care)

Interventions

  • DrugLabetalol or Nifedipine

    The choice of anti-HTN will be based on the patient and provider's experience and preference. First line anti-HTN recommended in pregnancy- labetalol or nifedipine- will be administered to patients. At least weekly, a study team member will review the participants' BPs and, if randomized to intervention and a higher dose is needed to maintain BPs \<130/80 mmHg, the study team member will communicate with the clinical team, led by a University of Alabama Maternal Fetal Medicine Attending, in order to ensure coordination between the research and clinical care teams. Labetalol will be initiated at 200 mg twice daily and escalated in 200mg /dose daily until BP\<130/80mmHg to a maximum dose of 2400mg/day. Procardia will be initiated at 30mg XL once daily and uptitrated in 30mg increments until a maximum dose of 120mg daily. Postpartum, titration will occur in similar fashion. The patient will be transitioned to her primary care provider for BP management after the 6-week postpartum visit.

06

What researchers measure

Primary outcomes

  1. Neonatal Birthweight percentile

    To determine whether anti-HTN treatment to BP\<130/80mmHg in pregnant patients with Stage 1 HTN is associated with a difference in birthweight percentile at delivery

    Time frame: at delivery of infant

07

Study locations

1 of 1 sites recruiting
  • UAB
    Birmingham, Alabama 35294, United States
    Recruiting
    • Donna Campbell · Contactdcampbell@uabmc.edu · (205) 996-6268
    • Victoria Jauk · Contactvchapman@uab.edu · 334-477-1740
    • Rachel Sinkey, MD · Principal investigator
    • Ayodeji Sanusi, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Aug 14, 2023
StartActual
Apr 24, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05989581
Responsible party
Rachel Sinkey (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Aug 14, 2023
Start date
Apr 24, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 11, 2026

Study contacts

Donna Dunn, PhD
Contact
dcampbell@uabmc.edu
12058739503
Jhana Plump
Contact
jplump@uabmc.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion